Login to Your Account



Clinic Roundup


Thursday, January 20, 2011
Geron Corp., of Menlo Park, Calif., announced enrollment of the first patient in a Phase II trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription